Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 21, 2022

SELL
$4.75 - $7.5 $969 - $1,530
-204 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$5.02 - $6.59 $512 - $672
102 Added 100.0%
204 $2,000
Q2 2021

Jul 30, 2021

BUY
$5.79 - $8.6 $590 - $877
102 New
102 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.